Scarica l'app Stockscreener
79.96
3.38%
-2.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$82.76
Aprire:
$82.89
Volume 24 ore:
4.03M
Relative Volume:
0.78
Capitalizzazione di mercato:
$46.04B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
43.44
EPS:
1.8406
Flusso di cassa netto:
$1.34B
1 W Prestazione:
-4.79%
1M Prestazione:
-2.14%
6M Prestazione:
-4.11%
1 anno Prestazione:
+7.14%
Intervallo 1D:
$79.24
$83.04
Intervallo di 1 settimana:
$79.24
$84.64
Portata 52W:
$72.30
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
79.96 | 46.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
ABT
Abbott Laboratories
|
84.32 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
285.47 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
76.15 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.93 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Generali Asset Management SPA SGR Has $6.18 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE: EW) awards RSUs and options to CVP Daveen Chopra - Stock Titan
Edwards Lifesciences Corp (EW) Shares Fall 3.4% -- What GF Score of 97 Tells Investors - GuruFocus
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE: EW) investors approve equity and pay measures - Stock Titan
Swedbank AB Sells 192,442 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Principal Financial Group Inc. Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
QRG Capital Management Inc. Acquires 18,172 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE: EW) lifts Q1 2026 sales on TAVR and TMTT growth - Stock Titan
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences Appoints Theodora Mistras as Chief Financial Officer Effective May 2026 - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock - Investing.com UK
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) CVP Lippis sells 2,038 shares after option exercises - Stock Titan
Edwards Lifesciences (EW) executive logs 282-share tax withholding on Form 4 - Stock Titan
Edwards Lifesciences (EW) VP Donald Bobo logs tax share disposal and holdings - Stock Titan
Edwards Lifesciences names Doretta Mistras as new CFO - Investing.com
Theodora Mistras to Become Edwards Lifesciences CFO, Succeeding Scott Ullem - TradingView
New Edwards Lifesciences (NYSE: EW) CFO to receive $925K salary and major equity - Stock Titan
Edwards picks Viatris finance chief Doretta Mistras as CFO - Stock Titan
Edwards Lifesciences (NYSE: EW) files Form 144; insider disposals listed - Stock Titan
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock - Yahoo Finance
TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE - Yahoo Finance
PFA Pension Forsikringsaktieselskab Buys Shares of 543,261 Edwards Lifesciences Corporation $EW - MarketBeat
M&T Bank Corp Cuts Position in Edwards Lifesciences Corporation $EW - MarketBeat
After 10 years, Edwards valve tissue shows 97.9% freedom from deterioration - Stock Titan
Edwards Lifesciences Corporation $EW Stake Lessened by Kornitzer Capital Management Inc. KS - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Caisse Des Depots ET Consignations - MarketBeat
Exencial Wealth Advisors LLC Trims Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Barclays Lifts PT on Edwards Lifesciences Corporation (EW) Following Q1 Earnings - Insider Monkey
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Jennison Associates LLC Sells 178,259 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
How The Edwards Lifesciences (EW) Investment Story Is Shifting As Views On Growth Diverge - Yahoo Finance
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Vanguard (NYSE: EW) reports 43.48M shares, 7.54% stake in Edwards Lifesciences - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Edwards CEO speaks May 12, with live webcast and same-day replay - Stock Titan
AMG National Trust Bank Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Vanguard Group Inc. Sells 283,775 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
MDEV volume surges 14x as Edwards Lifesciences jumps - TipRanks
US28176EAD04 Bond Analysis — Key Metrics - TradingView
Munich Reinsurance Co Stock Corp in Munich Purchases 52,494 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
A Look at Edwards Lifesciences Corp (EW) After 5.6% Gain -- GF V - GuruFocus
Edwards Lifesciences Stock Surges On Heart Valve Devices Growth - Benzinga
Edwards raises 2026 guidance on strong TAVR performance - BioWorld News
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.47%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):